3
Announcements
Trials
Browse
Landscape
Status
Completed
13
Recruiting
7
Active not recruiting
7
Terminated
4
Withdrawn
3
No longer available
1
Approved for marketing
1
Sponsor Class
OTHER
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
nilotinib
4
midostaurin
3
venetoclax
2
navitoclax
2
fludarabine phosphate
2
revumenib
1
ponatinib
1
magrolimab
1
gilteritinib
1
fludarabine
1
eryaspase
1
enasidenib
1
asparaginase erwinia chrysanthemi recombinant
1
Whole-Body Irradiation
1
Transplantation
1
Tacrolimus
1
Mycophenolic Acid
1
Cytarabine
1
Cyclophosphamide
1
Cord Blood Stem Cell Transplantation
1
Busulfan
1
Bone Marrow Transplantation
1
Asparaginase
1
AP 1903 reagent
1
4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
No longer available
×
asparaginase erwinia chrysanthemi recombinant
×
Other hematologic neoplasm
×
Clear all
NCT00590915
2026-01-23
EMTP
Phoenix Children's Hospital
No longer available